ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.30
+0.16 (2.24%)
At close: Apr 2, 2026, 4:00 PM EDT
7.24
-0.06 (-0.82%)
After-hours: Apr 2, 2026, 7:59 PM EDT
ImmunityBio Employees
As of December 31, 2025, ImmunityBio had 691 total employees, including 684 full-time and 7 part-time employees. The number of employees increased by 11 or 1.62% compared to the previous year.
Employees
691
Change
11
Growth
1.62%
Revenue / Employee
$163,948
Profits / Employee
-$508,535
Market Cap
7.54B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 691 | 11 | 1.62% | 684 | 7 |
| Sep 30, 2025 | 673 | 1 | 0.15% | 673 | 0 |
| Jun 30, 2025 | 685 | 63 | 10.13% | 685 | 0 |
| Mar 31, 2025 | 671 | 43 | 6.85% | 671 | 0 |
| Dec 31, 2024 | 680 | 52 | 8.28% | 680 | 0 |
| Sep 30, 2024 | 672 | 2 | 0.30% | 672 | 0 |
| Jun 30, 2024 | 622 | -61 | -8.93% | 622 | 0 |
| Mar 31, 2024 | 628 | -75 | -10.67% | 628 | 0 |
| Dec 31, 2023 | 628 | -97 | -13.38% | 628 | 0 |
| Sep 30, 2023 | 670 | -90 | -11.84% | 670 | 0 |
| Jun 30, 2023 | 683 | -57 | -7.70% | 683 | 0 |
| Mar 31, 2023 | 703 | 15 | 2.18% | 703 | 0 |
| Dec 31, 2022 | 725 | 138 | 23.51% | 725 | 0 |
| Sep 30, 2022 | 760 | 222 | 41.26% | 760 | 0 |
| Jun 30, 2022 | 740 | 229 | 44.81% | 740 | 0 |
| Mar 31, 2022 | 688 | 213 | 44.84% | 688 | 0 |
| Dec 31, 2021 | 587 | 112 | 23.58% | 587 | 0 |
| Sep 30, 2021 | 538 | 273 | 103.02% | 538 | 0 |
| Jun 30, 2021 | 511 | 246 | 92.83% | 511 | 0 |
| Mar 31, 2021 | 475 | 210 | 79.25% | 475 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Apogee Therapeutics | 261 |
| Kymera Therapeutics | 238 |
| Nuvalent | 228 |
IBRX News
- 2 days ago - ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PRNewsWire
- 3 days ago - ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline - Business Wire
- 7 days ago - $IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses - GlobeNewsWire
- 8 days ago - ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - Benzinga
- 8 days ago - ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 - Business Wire
- 10 days ago - ImmunityBio stock price crash: buy the dip or sell the rip? - Invezz
- 10 days ago - ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 10 days ago - ImmunityBio Crashes On FDA Warning Over Anktiva Claims - Benzinga